A news item on Keryx Biopharmaceuticals Inc. in the Nov. 1, 2000, issue of BioWorld International should have said the company plans to take KRX-123 into Phase I trials in Israel after getting regulatory clearance there, not that it got U.S. approval for the study. Also, the company said it received FDA approval to proceed to Phase III trial design for KRX-101 in the U.S., not to initiate the trial.

Editor's Note: The corrections already were made in BioWorld Online.

No Comments